Related Experiment Video
Updated: Nov 12, 2025
09:30
Treating Clinical Depression with Repetitive Deep Transcranial Magnetic Stimulation Using the Brainsway H1-coil
Published on: October 4, 2016
22.6K
Repetitive Transcranial Magnetic Stimulation for Treatment-Resistant Depression: Recent Critical Advances in Patient
Camila Cosmo1,2, Amin Zandvakili1,2, Nicholas J Petrosino1,2
1VA RR&D Center for Neurorestoration and Neurotechnology, Providence VA Healthcare System, 830 Chalkstone Ave, Providence, 02908 USA.
Current Treatment Options in Psychiatry
|March 16, 2021
Summary
Repetitive transcranial magnetic stimulation (rTMS) is an effective treatment for major depressive disorder (MDD). Newer methods like theta burst TMS and advanced targeting show promise for optimizing outcomes and reducing treatment time.
Area of Science:
- Neuroscience
- Psychiatry
- Medical Technology
Background:
- Transcranial magnetic stimulation (TMS) is an established treatment for major depressive disorder (MDD) resistant to medication.
- Recent advancements have refined the understanding and application of TMS technology.
Purpose of the Study:
- To review large, randomized controlled studies supporting the current use of repetitive TMS (rTMS) for MDD.
- To discuss the application of TMS technologies during the COVID-19 pandemic.
Main Methods:
- Review of randomized controlled studies on rTMS for MDD.
- Analysis of emerging technologies and approaches in TMS therapy.
Main Results:
- Theta burst TMS is non-inferior to standard TMS, offering administration advantages.
- Neuroimaging may enhance TMS targeting and patient selection for optimal response.
Conclusions:
- Further research is needed to individualize and optimize TMS procedures.
- Accelerated TMS and advanced targeting require more validation for clinical utility.
- Safe TMS administration during the pandemic is feasible with strict safety protocols.
